跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Pearl Therapeutics, Inc.

首页临床试验发起方与机构Pearl Therapeutics, Inc.

Pearl Therapeutics, Inc.

ACTIVE

新泽西州摩里斯县, New Jersey, 美国www.pearltherapeutics.comSubsidiary51–100 名员工成立于: 2006-01-01

别名:

pearl therapeutics, inc. (pearl)

隶属于阿斯利康

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

85

29 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

2006

概览

试验阶段分布

阶段

试验数

占比

1 期

38

44.7%

3 期

27

31.8%

2 期

16

18.8%

不适用

3

3.5%

试验状态分布

进行中（未招募）

28

32.9%

已完成

45

52.9%

尚未招募

1

1.2%

终止

1

1.2%

撤回

2

2.4%

相关临床试验

该机构主办的试验（85）

A Study to Assess the Efficacy and Safety of PT009 compared to PT005 in Subjects with Moderate to Very Severe COPD (Sophos)

进行中（未招募）

Sep 20211843 名受试者

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations in Subjects With Moderate to Very Severe COPD

进行中（未招募）

Jul 20218588 名受试者

A Randomized, Double-Blind, Parallel Group, Multi-Center 24 Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma

进行中（未招募）

Feb 20201071 名受试者

A Randomized, Double-Blind, Chronic Dosing (7-Day), Four-Period, Four-Treatment, Placebo-Controlled, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD

A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort Turbuhaler as an Active Control (PT010007)

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort Turbuhaler as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PT010006)

A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos) (PT010005)

Aug 20188400 名受试者

A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo (PT003014)

第 1 页，共 11 页

药物批准

暂无批准数据

资讯

暂无资讯文章

本页目录

概览
相关临床试验85
药物批准
资讯

返回机构列表